Patient-derived bladder cancer xenografts: A systematic review

Translational Research

Volumn 166, Issue 4, 2015, Pages 324-331

  Bernardo, Carina ^a,b   Costa, Céu ^a,c   Sousa, Nuno ^a   Amado, Francisco ^b   Santos, Lúcio ^a,c  

^a PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^b UNIVERSITY OF AVEIRO   (Portugal)

^c UNIVERSIDADE FERNANDO PESSOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PROTEIN P53;

BLADDER CANCER; CANCER PATIENT; CELL SUSPENSION; CHROMOSOME ANALYSIS; DRUG SCREENING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; METASTASIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; TISSUE PRESERVATION; TUMOR XENOGRAFT; XENOTRANSPLANTATION; ANIMAL; BLADDER TUMOR; META ANALYSIS; MOUSE; PATHOLOGY; XENOGRAFT;

ANIMALS; HUMANS; MICE; TRANSPLANTATION, HETEROLOGOUS; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941316367     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2015.02.001     Document Type: Review

References (34)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. M. Knowles What we could do now: molecular pathology of bladder cancer Mol Pathol 54 2001 215 221
3. J. Bellmunt, S. Albiol, and V. Kataja Invasive bladder cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 suppl 4 2009 79 80
4. H.H. Fiebig, A.W. Dengler, and T. Roth Human tumor xenografts: predictivity, characterization and discovery of new anticancer agents H.H. Fiebig, A.M. Burg, Relevance of tumor models for anticancer drug development Contr Oncol Basel 54 1999 Karger 29 50
5. B. Rubio-Viqueira, and M. Hidalgo Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients Clin Pharmacol Ther 85 2009 217 221
6. X. Dong, J. Guan, J.C. English, and et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy Clin Cancer Res 16 2010 1442 1451
7. M. Hidalgo, E. Bruckheimer, N.V. Rajeshkumar, and et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer Mol Cancer Ther 10 2011 1311 1316
8. I. Fichtner, W. Slisow, J. Gill, and et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas Eur J Cancer 40 2004 298 307
9. D. Mischek, R. Steinborn, H. Petznek, and et al. Molecularly characterised xenograft tumour mouse models: valuable tools for evaluation of new therapeutic strategies for secondary liver cancers J Biomed Biotechnol 2009 2009 437284
10. J. Merk, J. Rolff, M. Becker, G. Leschber, and I. Fichtner Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 36 2009 454 459
11. A. Jimeno, G. Feldmann, A. Suárez-Gauthier, and et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development Mol Cancer Ther 8 2009 310 314
12. P.J. Russell, D. Raghavan, P. Gregory, and et al. Bladder cancer xenografts: a model of tumor cell heterogeneity Cancer Res 46 1986 2035 2040
13. P.J. Russell, D. Raghavan, J. Philips, and P. Gregory Applications of the xenograft as a model of invasive transitional cell carcinoma of the bladder Prog Clin Biol Res 260 1988 167 181
14. A. Kovnat, M. Armitage, and I. Tannock Xenografts of human bladder cancer in immune-deprived mice Cancer Res 42 1982 3696 3703
15. A. Kovnat, R.N. Buick, J.G. Connolly, M.A. Jewett, A.G. Keresteci, and I.F. Tannock Comparison of growth of human bladder cancer in tissue culture or as xenografts with clinical and pathological characteristics Cancer Res 44 1984 2530 2533
16. H. Zhang, O.H. Aina, K.S. Lam, and et al. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach Urol Oncol 30 2012 635 645
17. X. He, L. Marchionni, D.E. Hansel, and et al. Differentiation of a highly tumorigenic basal cell compartment in urothelial carcinoma Stem Cells 27 2009 1487 1495
18. T.Y. Lin, Y.P. Li, H. Zhang, and et al. Tumor-targeting multifunctional micelles for imaging and chemotherapy of advanced bladder cancer Nanomedicine (Lond) 8 2012 1239 1251
19. H.A. Azar, S.B. Fernandez, L.M. Bros, and J.L. Sullivan Human tumor xenografts in athymic (nude) mice: chemotherapy trials in serially transplanted tumors Ann Clin Lab Sci 12 1982 51 59
20. P.N. Matthews, A.G. Grant, and J. Hermon-Taylor The growth of human bladder and kidney cancers as xenografts in nude mice and rats Urol Res 10 1982 293 299
21. K.S. Chan, I. Espinosa, M. Chao, and et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells Proc Natl Acad Sci U S A 106 2009 14016 14021
22. J.H. Hay, A. Busuttil, C.M. Steel, and W. Duncan The growth and histological characteristics of a series of human bladder cancer xenografts Radiother Oncol 7 1986 331 340
23. T. Abe, M. Tada, N. Shinohara, and et al. Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice Int J Urol 13 2006 47 57
24. T. Hofner, S. Macher-Goeppinger, C. Klein, and et al. Development and characteristics of preclinical experimental models for the research of rare neuroendocrine bladder cancer J Urol 190 2013 2263 2270
25. C. Bernardo, C. Costa, T. Amaro, and et al. Patient-derived sialyl-Tn-positive invasive bladder cancer xenografts in nude mice: an exploratory model study Anticancer Res 34 2014 735 744
26. G. Sufrin, M. McGarry, A. Sandberg, and G. Murphy Heterotransplantation of human transitional cell carcinoma in athymic mice J Urol 121 1979 159 161
27. S. Naito, A. Iwakawa, K. Tanaka, and et al. Heterotransplantation of human urinary bladder cancers in nude mice Invest Urol 18 1981 285 288
28. P.A. McCue, L.G. Gomella, R.W. Veltri, G.M. Marley, M.C. Miller, and E.C. Lattime Development of secondary structure, growth characteristics and cytogenetic analysis of human transitional cell carcinoma xenografts in SCID/SCID mice J Urol 155 1996 1128 1132
29. B. Park, B.C. Jeong, Y.L. Choi, and et al. Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue Cancer Sci 104 2013 1 8
30. J.I. Johnson, S. Decker, D. Zaharevitz, and et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials Br J Cancer 84 2001 1424 1431
31. J.J. Tentler, A.C. Tan, C.D. Weekes, and et al. Patient-derived tumour xenografts as models for oncology drug development Nat Rev Clin Oncol 9 2012 338 350
32. J.K. Peterson, and P.J. Houghton Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development Eur J Cancer 40 2004 837 844
33. T. Voskoglou-nomikos, J.L. Pater, and L. Seymour Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models Clin Cancer Res 9 2003 4227 4239
34. S.C. Smith, A.S. Baras, J.K. Lee, and D. Theodorescu The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer Cancer Res 70 2010 1753 1758